@article{8cda337524b54d0bab270cb795a13fac,
title = "Overcoming Endocrine Resistance in Breast Cancer",
abstract = "Estrogen receptor-positive (ER+) breast cancer is the most common breast cancer subtype. Treatment of ER+ breast cancer comprises interventions that suppress estrogen production and/or target the ER directly (overall labeled as endocrine therapy). While endocrine therapy has considerably reduced recurrence and mortality from breast cancer, de novo and acquired resistance to this treatment remains a major challenge. An increasing number of mechanisms of endocrine resistance have been reported, including somatic alterations, epigenetic changes, and changes in the tumor microenvironment. Here, we review recent advances in delineating mechanisms of resistance to endocrine therapies and potential strategies to overcome such resistance.",
keywords = "ESR1, SERD, SERM, aromatase inhibitor, breast cancer, endocrine resistance, estrogen receptor",
author = "Hanker, {Ariella B.} and Sudhan, {Dhivya R} and Arteaga, {Carlos L.}",
note = "Funding Information: A.B.H. receives research grant support from Takeda . C.L.A. receives or has received research grants from Puma Biotechnology , Pfizer , Lilly , Bayer , Takeda, and Radius ; holds stock options in Provista and Y-TRAP; serves or has served in an advisory role to Novartis, Merck, Lilly, Symphogen, Daiichi Sankyo, Radius, Taiho Oncology, H3Biomedicine, OrigiMed, Puma Biotechnology, and Sanofi; and reports scientific advisory board remuneration from the Komen Foundation. Funding Information: We thank Donald McDonnell for assistance in compiling Table 2. The authors are funded by UTSW Simmons Cancer Center P30 CA142543 , CPRIT RR170061 (C.L.A.), NCI Breast SPORE P50 CA098131 , Susan G. Komen Breast Cancer Foundation SAC100013 (C.L.A.), Breast Cancer Research Foundation (C.L.A.), and NCI R01CA224899 (A.B.H. and C.L.A.). Publisher Copyright: {\textcopyright} 2020 Elsevier Inc.",
year = "2020",
month = apr,
day = "13",
doi = "10.1016/j.ccell.2020.03.009",
language = "English (US)",
volume = "37",
pages = "496--513",
journal = "Cancer Cell",
issn = "1535-6108",
publisher = "Cell Press",
number = "4",
}